[Features of clinical manifestations of salivary gland pathology in patients after radioiodine therapy].

Q4 Medicine
A Ya Razumova, A I Yaremenko, S I Kutukova, E V Borodavina, N L Petrov, S A Yaremenko
{"title":"[Features of clinical manifestations of salivary gland pathology in patients after radioiodine therapy].","authors":"A Ya Razumova, A I Yaremenko, S I Kutukova, E V Borodavina, N L Petrov, S A Yaremenko","doi":"10.17116/stomat202510404112","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim the study is determination of the features of the manifestations of sialadenitis that developed during or after radioiodine therapy.</p><p><strong>Material and methods: </strong>We analyzed the data of 61 patients who received at least one session of radioiodine therapy. The patients were divided into two groups: with and without salivary gland pathology. Patients in the control group underwent scintigraphy and ultrasound examination of the soft tissues of the maxillofacial region and neck, as well as salivary gland structures, once every 3 months (in remission - once a year). When obstruction of the ductal system of the salivary glands was detected, patients underwent diagnostic sialoscopy.</p><p><strong>Results: </strong>A bilateral lesion of the parotid salivary gland was found in 10 (36%) patients. Damage to the salivary glands developed after receiving at least one dose of radioiodine therapy (2.56 Gbq). The main complaint was an enlargement of the salivary gland. The first symptoms of the disease appeared at initial doses of radionuclide therapy not exceeding 6.77 Gbq(at the minimum dose 2.56 Gbq): the median time for the first symptoms of salivary gland disease was 14.5 (95% CI 11.0-113.0) months (<i>p</i><0.0001).</p><p><strong>Conclusion: </strong>The main clinical signs of sialadenitis, which broke down against the background of radioiodine therapy, are impaired saliva outflow, as well as xerostomia. Therefore, the treatment of this pathology should be aimed at restoring the patency of the ductal system and stimulating saliva production.</p>","PeriodicalId":35887,"journal":{"name":"Stomatologiya","volume":"104 4","pages":"12-16"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stomatologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/stomat202510404112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The aim the study is determination of the features of the manifestations of sialadenitis that developed during or after radioiodine therapy.

Material and methods: We analyzed the data of 61 patients who received at least one session of radioiodine therapy. The patients were divided into two groups: with and without salivary gland pathology. Patients in the control group underwent scintigraphy and ultrasound examination of the soft tissues of the maxillofacial region and neck, as well as salivary gland structures, once every 3 months (in remission - once a year). When obstruction of the ductal system of the salivary glands was detected, patients underwent diagnostic sialoscopy.

Results: A bilateral lesion of the parotid salivary gland was found in 10 (36%) patients. Damage to the salivary glands developed after receiving at least one dose of radioiodine therapy (2.56 Gbq). The main complaint was an enlargement of the salivary gland. The first symptoms of the disease appeared at initial doses of radionuclide therapy not exceeding 6.77 Gbq(at the minimum dose 2.56 Gbq): the median time for the first symptoms of salivary gland disease was 14.5 (95% CI 11.0-113.0) months (p<0.0001).

Conclusion: The main clinical signs of sialadenitis, which broke down against the background of radioiodine therapy, are impaired saliva outflow, as well as xerostomia. Therefore, the treatment of this pathology should be aimed at restoring the patency of the ductal system and stimulating saliva production.

[放射碘治疗后患者涎腺病理的临床表现特点]。
目的:探讨放射碘治疗期间或治疗后涎腺炎的临床表现特点。材料和方法:我们分析了61例至少接受过一次放射性碘治疗的患者的资料。将患者分为有和无唾液腺病理两组。对照组患者每3个月(缓解期-每年1次)对颌面部及颈部软组织及唾液腺结构进行扫描和超声检查。当检测到唾液腺导管系统阻塞时,患者进行诊断性涎镜检查。结果:双侧腮腺涎腺病变10例(36%)。在接受至少一剂放射性碘治疗(2.56 Gbq)后,唾液腺出现损伤。主要的主诉是唾液腺肿大。在放射性核素治疗初始剂量不超过6.77 Gbq(最低剂量为2.56 Gbq)时出现首发症状,出现涎腺疾病首发症状的中位时间为14.5个月(95% CI 11.0-113.0)。结论:涎腺炎在放射性碘治疗背景下的主要临床症状为唾液流出受损和口干。因此,这种病理的治疗应着眼于恢复导管系统的通畅和刺激唾液的产生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Stomatologiya
Stomatologiya Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
93
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信